Loomis Sayles & Co. L P Purchases 62,969 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Loomis Sayles & Co. L P boosted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 59.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 169,621 shares of the specialty pharmaceutical company's stock after buying an additional 62,969 shares during the period. Loomis Sayles & Co. L P owned approximately 0.28% of Jazz Pharmaceuticals worth $20,889,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. IFP Advisors Inc acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $25,000. CoreFirst Bank & Trust purchased a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $28,000. Jones Financial Companies Lllp increased its stake in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 130 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after buying an additional 129 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its stake in shares of Jazz Pharmaceuticals by 82.6% during the fourth quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company's stock worth $48,000 after buying an additional 176 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JAZZ. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Barclays reaffirmed an "overweight" rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. HC Wainwright boosted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Finally, Morgan Stanley reissued an "overweight" rating and set a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Trading Up 1.5 %

Shares of JAZZ stock traded up $1.90 during mid-day trading on Wednesday, hitting $126.89. 324,569 shares of the company's stock were exchanged, compared to its average volume of 740,704. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The stock has a 50-day simple moving average of $132.43 and a two-hundred day simple moving average of $122.90. The stock has a market cap of $7.71 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 1.04 and a beta of 0.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the transaction, the chief accounting officer now directly owns 7,012 shares of the company's stock, valued at approximately $966,323.72. The trade was a 13.98 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,736 shares of company stock valued at $4,022,825. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.